Home » Pfizer and Dewpoint Partner for Rare Muscle Disorder Therapeutics
Pfizer and Dewpoint Partner for Rare Muscle Disorder Therapeutics
Pfizer and Dewpoint Therapeutics are teaming up to develop potential therapeutics for myotonic dystrophy type 1 (DM1), a form of muscular dystrophy.
The rare genetic disease, known as Steinert disease, is one of two types of myotonic dystrophy and causes progressive muscle weakness and wasting beginning in a patient’s 20s or 30s.
Under the arrangement, Dewpoint will receive an upfront payment and potential future milestone payments totaling $239 million, plus royalties from any approved products.
Upcoming Events
-
07May
-
14May
-
30May